MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies
‒ Voruciclib alone or in combination with venetoclax was generally well tolerated with no significant myelosuppression ‒ – Encouraging preliminary efficacy signal demonstrated... | May 23, 2023
Richard Ghalie Pharma Inc Safety Review Committee National Cancer Institute Dan Gold Preliminary Safety
Source: marketscreener.com